• Osaretin Emmanuel Asowata, Olubisi Titilayo Ashiru, A Willem Sturm, and Prashini Moodley.
• Department of Medical Microbiology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal.
• Afr Health Sci. 2019 Jun 1; 19 (2): 199319991993-1999.

BackgroundRotavirus infection and its associated hospitalization of children less than 5 years old in middle- and low-income countries remains a public health challenge. We hypothesized that the Rotarix®potency is affected by non-optimal temperatures which translates into reduced vaccine effectiveness in these settings.ObjectiveTo assess the effect of non-optimal temperatures on the potency of the Rotarix® vaccine in South Africa.MethodsRotarix® vaccine was exposed to temperatures reflecting breaches in the cold chain. Vero cells (ATCC CCL-81) grown in a 24-well tissue culture plates were infected with Rotarix® vaccine viruses after exposure to non-optimal temperatures and the potency of the vaccine was determined using the plaque assay.ResultsExposure of the Rotarix® vaccine to seasonal temperatures in KwaZulu-Natal for 6 hours and to extreme temperatures of 40oC for 72 hours as well as to -20°C and -80°C for 12 hours did not affect the potency of the vaccine beyond its expected standard of >7 x 105 PFU/ml.ConclusionThis study revealed that the Rotarix® vaccine remains potent even after exposure to non-optimal temperatures. However, this study only explored the effect of a constant 'adverse' temperature on vaccine potency and not the effect of temperature fluctuations.© 2019 Asowata et al.

11 keywords...

hide…